I'd gladly take a smoker's lungs and risk cancer - to end the hell of life on the waiting list

Cystic Fibrosis sufferer Poppy Roberts, 23, from Monmouth would rather risk with smoker's lungs after waiting for two years for a transplant.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

A 39-year-old non-smoker woman was admitted in the thoracic oncology unit of the Montpellier Academic Hospital in June 2017 for investigation of multiple lung consolidations, fever, and respiratory failure. She was followed-up since infancy for a cystic fibrosis with cystic fibrosis transmembrane conductance regulator (CFTR) mutation ( ΔF508-CFTR). Two years ago, a lung allograft was decided, owing to rapid onset of respiratory function impairment, and she received a bi-pulmonary transplant. According to the donor database, the lung transplant was removed from a 57-year-old woman with a 30 pack-year smoking history.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This article is protected by copyright. All rights reserved. PMID: 29700855 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transplant Source Type: research
Cystic fibrosis and non-cystic fibrosis bronchiectasis share as their main clinical hallmark repeated lung infections by opportunist pathogens. In the normal adult lung, almost no lymphoid tissue is observed, in contrast to fetal and paediatric lungs [1] and in contrast to upper airways [2]. Neogenesis of bronchial-associated lymphoid tissue (BALT), also referred to as induced BALT (iBALT) or ectopic lymphoid follicles, has been observed in several chronic lung diseases, including chronic obstructive pulmonary disease (COPD) [3], lung cancer [4], pulmonary hypertension [5], post-transplant restrictive allograft syndrome [6...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: CF and non-CF bronchiectasis Editorials Source Type: research
We describe cancer incidence among CF and non-CF lung recipients.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: Tags: Original Article Source Type: research
ConclusionIn patients with incidentally detected early stage lung cancer at the time of LuTX, rates of recurrence and survival based on this sample appear to be acceptable.
Source: Clinical Transplantation - Category: Transplant Surgery Authors: Tags: Original Article Source Type: research
ConclusionIn patients with incidentally detected early stage lung cancer at the time of LuTX, rates of recurrence and survival based on this sample appear to be acceptable.
Source: Clinical Transplantation - Category: Transplant Surgery Authors: Tags: Original Article Source Type: research
ConclusionIn patients with incidentally detected early stage lung cancer at the time of LuTX, rates of recurrence and survival based on this sample appear to be acceptable.This article is protected by copyright. All rights reserved
Source: Clinical Transplantation - Category: Transplant Surgery Authors: Tags: Original Article Source Type: research
This article is protected by copyright. All rights reserved.
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: Letter to the Editor Source Type: research
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases. The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan&...
Source: Policy and Medicine - Category: American Health Authors: Source Type: blogs
Abstract Solid organ transplant recipients have increased colorectal cancer (CRC) risk. We assessed CRC risk among transplant recipients and identified factors contributing to this association. The US transplant registry was linked to 15 population‐based cancer registries (1987–2010). We compared CRC risk in recipients to the general population by using standardized incidence ratios (SIRs) and identified CRC risk factors by using Poisson regression. Based on 790 cases of CRC among 224 098 transplant recipients, the recipients had elevated CRC risk (SIR 1.12, 95% confidence interval [CI] 1.04 to 1.20). The increase ...
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Cystic Fibrosis | Health | Lung Transplant | Smokers | Transplants